01642oam 2200493 450 991071356240332120200520102346.0(CKB)5470000002502038(OCoLC)966433932(OCoLC)995470000002502038(EXLCZ)99547000000250203820161219d1986 ua 0engurbn|||||||||txtrdacontentcrdamediacrrdacarrierAtlas of the distributions and abundances of common benthic species in San Francisco Bay, California /by Dale R. HopkinsReston, Virginia :U.S. Geological Survey,1986.1 online resource (1 volumes (various pagings) mapsWater-resources investigations report ;86-4003"February 1986."Chiefly tables.Includes bibliographical references (pages 6-10).BenthosCaliforniaSan Francisco BayInvertebratesCaliforniaSan Francisco BayBenthosfastInvertebratesfastPacific OceanSan Francisco BayfastBenthosInvertebratesBenthos.Invertebrates.Hopkins Dale R.1420155Geological Survey (U.S.),COPCOPOCLCOOCLCFGPOBOOK9910713562403321Atlas of the distributions and abundances of common benthic species in San Francisco Bay, California3537027UNINA04654nam 2201261z- 450 991055730400332120220111(CKB)5400000000042816(oapen)https://directory.doabooks.org/handle/20.500.12854/76438(oapen)doab76438(EXLCZ)99540000000004281620202201d2021 |y 0engurmn|---annantxtrdacontentcrdamediacrrdacarrierPaediatric Formulation: Design and DevelopmentBasel, SwitzerlandMDPI - Multidisciplinary Digital Publishing Institute20211 online resource (205 p.)3-0365-0740-X 3-0365-0741-8 The development of paediatric medicines can be challenging since this is a different patient population with specific needs. A medicine designed for use in paediatric patients must consider the following aspects: patient population variability; the need for dose flexibility; route of administration; patient compliance; excipient tolerability. For example, the toxicity of excipients may differ in children compared to adults and children have different taste preferences. Globally, about 75% of drugs do not carry regulatory approval for use in children; worldwide, many medications prescribed for the treatment of paediatric diseases are used off-label, and less than 20% of package inserts have sufficient information for treating children. This book provides an update on both state-of-the-art methodology and operational challenges in paediatric formulation design and development. It aims at re-evaluating what is needed for more progress in the design and development of age-appropriate treatments for paediatric diseases, focusing on: formulation development; drug delivery design; efficacy, safety, and tolerability of drugs and excipients.Paediatric FormulationMedicinebicsscacceptableadministrationage-relatedanakinraautoinflammatory diseasebioavailabilitybiopharmaceuticscanakinumabchildchildrenchronic myeloid leukemiaconfocal microscopycyclodextrin inclusion complexdasatinibdesigndesign of experimentsdevelopmentdevicedosage formdrug deliveryDuchenne muscular dystrophyedible filmsexcipientflavor profileformulationformulation developmentgrindingimatinibinhaledinnovative biotechnologiesInterleukin-1intra nasalKawasaki diseaseliquid formulationmedication errormodified releaseneglected tropical diseasesneonatesNICUnilotinbNorvir®oralOrodispersible formulationpaediatricpaediatric agepaediatric dosage formspaediatric formulation developmentpalatability assessmentpalatableparenteralpediatricpediatric agepediatric drug deliverypediatricspenetrationpersonalized medicinephase solubility studiespolymorphponatinibpoorly soluble compoundpoorly water soluble drugproduct developmentpyrazinamideretinoblastomaritonavirsolubility enhancementspray congealingsystemic juvenile idiopathic arthritistaste-maskingtopicaltopotecantuberculosistumorspherestyrosine kinase inhibitorsMedicineDenora Nunzioedt1322374Lopalco AntonioedtDenora NunzioothLopalco AntonioothBOOK9910557304003321Paediatric Formulation: Design and Development3034926UNINA